Compare Inovio Pharmaceuticals Inc (INO) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Gartner Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.11 (market cap $119.42M), while Gartner Inc trades at $195.41 (market cap $11.73B). The key difference: Gartner Inc is far larger — about 98.2× Inovio Pharmaceuticals Inc's market cap, and Gartner Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Gartner Inc for 64 Days on average.
| INO | IT | |
|---|---|---|
Market Cap | $119.42M | $11.73B |
Volume | 2,789,649 | 736,899 |
Sector | Health | Technology |
52-Week High | $2.65 | $258.17 |
52-Week Low | $0.66 | $125.68 |
Typical Hold Time | 43 Days | 64 Days |
Enterprise Value | $90.75M | $13.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
Gartner (IT) trades at $185.77, up 0.46% today, showing strong technical momentum with a bullish moving average signal. The company maintains robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and impressive profitability metrics including 69.63% gross margin and 113.58% ROE. Recent news highlights Gartner's leadership position in AI advisory services and strong industry recognition.
While valuation appears reasonable with P/E of 16.71, the stock faces headwinds from negative cash flow trends and a high P/B ratio of 160.06. Analyst consensus is mixed with 27.78% buy ratings but a consensus price target below current levels at $174.63, suggesting limited near-term upside potential despite strong business fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
